Using Proteome Microarray and Gene Expression Omnibus Database to Screen Tumour-associated Antigens to Construct the Optimal Diagnostic Model of Oesophageal Squamous Cell Carcinoma
This study was designed to screen and verify autoantibodies against TAAs in sera as diagnostic biomarkers for oesophageal squamous cell carcinoma (ESCC). (Source: Clinical Oncology)
Source: Clinical Oncology - July 5, 2023 Category: Radiology Authors: Guiying Sun, Hua Ye, Qian Yang, Jicun Zhu, Cuipeng Qiu, Jianxiang Shi, Liping Dai, Keyan Wang, Peng Wang, Jianying Zhang Tags: Original Article Source Type: research
OncoFlash – Research Updates in a Flash! (August 2023 Edition)
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. Zarif, T et al. Journal of Clinical Oncology, 2023 [1]. (Source: Clinical Oncology)
Source: Clinical Oncology - July 1, 2023 Category: Radiology Authors: C. Crockett, R. Sim ões Source Type: research
RCR Meetings
(Source: Clinical Oncology)
Source: Clinical Oncology - July 1, 2023 Category: Radiology Source Type: research
Extra-mandibular osteoradionecrosis after the treatment of head and neck cancer
Osteoradionecrosis (ORN) is a serious toxicity of head and neck radiotherapy. It predominantly affects the mandible. Extra-mandibular ORN is rare. The aim of this study was to report the incidence and outcomes of extra-mandibular ORNs from a large institutional database. (Source: Clinical Oncology)
Source: Clinical Oncology - June 27, 2023 Category: Radiology Authors: Petr Daniel Edward Kovarik, Rahul Patil, Jakub Cvek, Charles Kelly, Malcolm Jackson, Laura Mackenzie, Nick West, Nicholas Willis, Josef Paul Kovarik, Robert Banks, Matthew Kennedy, James Adams, Muhammad Shahid Iqbal Tags: Original Article Source Type: research
Function Preservation with Brachytherapy: Reviving the Art
(Source: Clinical Oncology)
Source: Clinical Oncology - June 19, 2023 Category: Radiology Authors: Agata Rembielak, Ashwini Budrukkar, Tomas Kron Tags: Editorial Source Type: research
Organ and function preservation in gastrointestinal malignancies
[AQ1]Radiation plays an important role in organ preservation for gastrointestinal malignancies, with a watch and wait strategy enabling surgery to be avoided in patients who are not suitable or who are refusing surgery. Brachytherapy boost allows the radiation dose to be escalated, which plays a pivotal role in the successful outcome of achieving organ preservation. Here we describe the role of brachytherapy in two common gastrointestinal malignancies (oesophagus and rectum). Their indications and how the brachytherapy procedures are carried out, together with the dose and fractionation commonly used are discussed. (Source: Clinical Oncology)
Source: Clinical Oncology - June 17, 2023 Category: Radiology Authors: Ranjan Sur, Ngu Wah Than, Amandeep Taggar, Raj Sripadam, Arthur Sun Myint Source Type: research
Role of Adjuvant Radiotherapy in Acinic Cell Carcinoma of the Salivary Glands: a Systematic Review
A systematic review was carried out to evaluate if adjuvant radiotherapy for acinic cell carcinomas (ACCs) of salivary glands improves survival. Twelve retrospective studies published between 2000 and 2020 that analysed the effect of radiotherapy on salivary gland neoplasms and ACCs of salivary glands and met the inclusion criteria were included in the review. The overall quality of the studies was moderate to low. There was no high-quality evidence for improved survival with radiotherapy for ACCs of the salivary gland. (Source: Clinical Oncology)
Source: Clinical Oncology - June 16, 2023 Category: Radiology Authors: R. Patil, L. Uzzaman, C. Kelly, J. Kovarik, M. Jackson, C. Paterson, S.P. Munro, A. Wilson, M.S. Iqbal Tags: Overview Source Type: research
Association of computed tomography radiomics signature with progression-free survival in neuroblastoma patients
To investigate the association of computed tomography radiomics signature with progression-free survival (PFS) in neuroblastoma patients. (Source: Clinical Oncology)
Source: Clinical Oncology - June 14, 2023 Category: Radiology Authors: Haoru Wang, Ting Li, Mingye Xie, Jiajun Si, Jinjie Qin, Yanlin Yang, Li Zhang, Hao Ding, Xin Chen, Ling He Tags: Original Article Source Type: research
Brachytherapy for Organ and Function Preservation in Soft-tissue Sarcomas in Adult and Paediatric Patients
Adjuvant radiotherapy is an integral component in the management of soft-tissue sarcomas. Brachytherapy is a very convenient and conformal way of delivering adjuvant radiotherapy in such tumours, which spares the surrounding normal tissue. Randomised studies have established the efficacy of brachytherapy in the adjuvant setting, with a 5-year local control of 80 –85%. High dose rate, low dose rate and pulsed dose rate have shown equivalent local control, but high dose rate has gained popularity owing to patient convenience, radiation safety and flexibility in dose optimisation. (Source: Clinical Oncology)
Source: Clinical Oncology - June 9, 2023 Category: Radiology Authors: S. Laskar, J.J. Manjali, C. Chargari, J. Chard Source Type: research
Palliative Radiotherapy for Haemostasis in Malignancy: a Systematic Review
Palliative radiotherapy is commonly used to achieve haemostasis for malignancy-induced haemorrhages. Our study aimed to examine the efficacy of palliative radiotherapy in the control of haemorrhages caused by various types of malignancy. (Source: Clinical Oncology)
Source: Clinical Oncology - June 9, 2023 Category: Radiology Authors: C. Brown, J. Song, K. Dennis, M. Gaudet, A. Haddad Tags: Original Article Source Type: research
Locoregional Control and Toxicity Following High-dose Hypofractionated and Accelerated Palliative Radiotherapy Regimens in Breast Cancer
For patients with locally advanced primary/recurrent breast cancer, radiotherapy is an effective treatment for locoregional control. 36 Gy in 6 Gy once-weekly fractions is a commonly used schedule, but there are no data comparing local control and toxicity between 36 Gy delivered once-weekly versus accelerated schedules of multiple 6 Gy fractions per week. Here we compared local control rates and acute and late toxicity in patients undergoing 30 –36 Gy in 6 Gy fractions over 6 weeks versus more accelerated schedules over 2–3 weeks for an unresected breast cancer. (Source: Clinical Oncology)
Source: Clinical Oncology - June 9, 2023 Category: Radiology Authors: K. Webb, L. Gothard, K. Mohammed, A.M. Kirby, I. Locke, N. Somaiah Tags: Original Article Source Type: research
OncoFlash – Research Updates in a Flash! (July 2023)
18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial. Cooke, S.A. et al.Radiotherapy and Oncology, 2023 [1]. (Source: Clinical Oncology)
Source: Clinical Oncology - June 8, 2023 Category: Radiology Authors: C. Lorimer, K.T. Jayaprakash Source Type: research
RCR Meetings
(Source: Clinical Oncology)
Source: Clinical Oncology - June 8, 2023 Category: Radiology Source Type: research
Differential Response of Pelvic Bone Marrow Fluorodeoxyglucose Uptake in Patients Receiving Concurrent Chemoradiotherapy
Irradiation of pelvic bone marrow (PBM) at the level of the typical low dose bath of intensity-modulated radiotherapy delivery (10 –20 Gy) is associated with an increased risk of haematological toxicity, particularly when combined with concurrent chemotherapy. Although sparing of the whole of the PBM at a 10–20 Gy dose level is unachievable, it is known that PBM is divided into haematopoietically active and inactive regions that are identifiable based on the threshold uptake of [18F]-fluorodeoxyglucose (FDG) seen on positron emission tomography-computed tomography (PET-CT). (Source: Clinical Oncology)
Source: Clinical Oncology - June 5, 2023 Category: Radiology Authors: M. Robinson, R. Muirhead, D.R. McGowan, K.-Y. Chu, C. Jacobs, M.A. Hawkins Tags: Original Article Source Type: research
Impact of the COVID-19 Pandemic on Radiotherapy Interruptions and Patient Outcomes
Sir — The insightful study by Grocutt et al. [1] captured our interest, as it highlighted a significant 10% decline in radical radiotherapy courses and a shift towards hypofractionated regimens during the first year of the COVID-19 pandemic in Scotland. While shedding light on the pandemic's indirect effects on radiotherapy services, the study also revealed unresolved issues that warrant careful attention. (Source: Clinical Oncology)
Source: Clinical Oncology - June 5, 2023 Category: Radiology Authors: C.X. Hsu, T.C. Li Tags: Letter Source Type: research
